Gene Solutions and Dingjing Bio Partner To Revolutionize Cancer screening In China
shanghai, June 12, 2025 – In a groundbreaking move set to transform cancer diagnostics, AsiaS leading biotech innovator, Gene Solutions, has announced a strategic alliance with Zhejiang Shaoxing Dingjing biomedical Technology Co., Ltd. This collaboration aims to introduce cutting-edge oncology solutions to enhance early cancer detection and treatment strategies throughout China.
Strategic Alliance To Boost Cancer Screening Capabilities
Dingjing Bio, a prominent Clinical Laboratory Enhancement Amendments (CLIA)-and College of American Pathologists (CAP)-certified laboratory in China, operates a thorough next-generation sequencing (NGS) platform, covering over 1,300 hospitals. This partnership will integrate Gene Solutions’ advanced oncology solutions,significantly expanding Dingjing Bio’s medical capabilities.
This collaboration will introduce innovative products,including:
- Spot-mas: A clinically validated multi-cancer early screening (MCED) blood test,facilitating early detection of various cancers.
- Spot-mas Lung: an accurate testing scheme designed for premature screening of lung cancer, addressing a critical need in respiratory health.
- K-4CARE: An integrated platform for genome and transcriptome analysis, utilizing circulating tumor DNA (ctDNA)-based micro-residual lesions (MRD) monitoring to support personalized therapeutic strategies and long-term disease management.
These advanced tools will enrich Dingjing Bio’s tumor detection offerings, providing it’s extensive hospital network with state-of-the-art cancer screening and management resources.
Statements From Leadership
Chen Weiqiang, Chairman of dingjing Bio, remarked, “This collaboration with Gene Solutions is expected to significantly enhance our technical capabilities in oncology detection and holds profound strategic value.We aim to promote the localization and change of new technologies, accelerate clinical research, and jointly expand into international markets.”
Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions, added, “China’s robust infrastructure and extensive hospital coverage make Dingjing bio an ideal partner for advancing accurate oncology applications. Together, we will integrate cutting-edge cancer genomics technologies into clinical practice, benefiting a wider patient population.”
Focus On Clinical Advancement
The collaboration will emphasize clinical verification, translational research, and joint commercialization, with a shared commitment to improving cancer treatment efficacy and health management across the region.
about Dingjing Bio
Dingjing Bio is a leading provider of comprehensive oncology solutions in China,headquartered in Shaoxing,zhejiang,with an R&D center in Shanghai and a production base in Anhui. The company serves over 1,300 cooperative hospitals and has served more than 100,000 patients across 30 provinces, cities, and autonomous regions. Dingjing Bio integrates technical platforms such as qPCR, NGS, dPCR, and flow cytometry, widely used in early cancer screening, concomitant diagnosis, genetic testing, and disease monitoring.
Did You Know? The global next-generation sequencing market is projected to reach $25.5 billion by 2025, driven by advancements in cancer diagnostics and personalized medicine.
About Gene Solutions
Gene Solutions is a multinational biotech company headquartered in Asia, known for merging artificial intelligence with circulating tumor DNA (ctDNA) technology to provide innovative cancer treatment solutions. Its proprietary research and CAP-certified laboratories drive advancements in oncology diagnosis and treatment, covering everything from early cancer detection to real-time treatment monitoring.
Vision For the Future
With strong regional influence and a commitment to accessible healthcare, Gene Solutions is reshaping cancer diagnosis and personalized treatment in the Asia-Pacific region.
Pro tip: Regular health check-ups, including cancer screening, are essential for early detection and improved treatment outcomes.
Transforming Cancer Care: A Closer Look at the Gene Solutions and Dingjing Bio Partnership
The partnership between Gene Solutions and Dingjing Bio represents a significant step forward in the fight against cancer in China. by combining their expertise and resources, these companies are poised to enhance early detection, improve treatment strategies, and ultimately save lives.
| Feature | Gene Solutions | Dingjing Bio |
|---|---|---|
| Expertise | AI-driven ctDNA technology, innovative cancer solutions | CAP-certified lab, NGS platform, extensive hospital network |
| Focus | early cancer detection, treatment monitoring | Oncology solutions, clinical research |
| Advantage | Cutting-edge technology, regional influence | Wide business network, localization capabilities |
How do you think this partnership will impact cancer treatment in your community? What other innovations do you see emerging in the field of cancer diagnostics?
The Evolving Landscape Of Cancer Screening
The field of cancer screening is constantly evolving, with new technologies and approaches emerging regularly. Liquid biopsies, like the Spot-mas test, are gaining prominence due to their non-invasive nature and ability to detect cancer at an early stage.Moreover, the integration of artificial intelligence (AI) is enhancing the accuracy and efficiency of diagnostic processes.
Governments and healthcare organizations worldwide are increasingly focusing on preventive care and early detection programs to reduce the burden of cancer. Collaborative efforts, such as the partnership between Gene Solutions and Dingjing Bio, are crucial for translating research findings into practical applications that benefit patients.
Frequently Asked Questions About Cancer Screening
- What is multi-cancer early screening (MCED)?
- Multi-cancer early screening (MCED) is a blood test designed to detect various types of cancer at an early stage,improving the chances of successful treatment.
- What is ctDNA-based micro-residual lesions (MRD) monitoring technology?
- CtDNA-based micro-residual lesions (MRD) monitoring technology uses circulating tumor DNA to track minimal residual disease after cancer treatment, helping to inform individualized therapeutic strategies.
- How does gene Solutions aim to improve cancer treatment?
- Gene Solutions aims to improve cancer treatment by providing innovative solutions for early cancer detection, real-time treatment monitoring, and personalized treatment plans through advanced genomic and AI-driven analysis.
- What is the role of CAP certification in cancer diagnostics?
- CAP (College of American Pathologists) certification ensures that laboratories meet high standards of quality and accuracy in their diagnostic testing processes,enhancing the reliability of cancer screening and treatment decisions.
- What are the benefits of early cancer screening?
- Early cancer screening can lead to earlier detection of the disease, increasing the likelihood of successful treatment and improving patient outcomes. Early detection may also reduce the need for aggressive treatments.
Share this article and join the conversation! What are your thoughts on this collaboration and its potential impact on cancer care?
